ProNAi Therapeutics (DNAI) IPO Opens Up 69%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
ProNAi Therapeutics (DNAI) Prices 8.1M Common Stock IPO at $17/Share
July 16, 2015 10:13 AM EDTProNAi Therapeutics, Inc. (Nasdaq: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the pricing of its initial public offering of 8,100,000 shares of its common stock at a price to the public of... More
IPOs for July 16th
July 15, 2015 3:58 PM EDTExpected IPOs for July 16th:
Innovation Economy (Nasdaq: MYIE - will offer 3.125 million shares and sees an offering price of $6.40 per shareProNAi Therapeutics, Inc. (Nasdaq: DNAI) - will offer 8.1 million shares and sees an offering price of $14.00 - $16.00 per... MoreProNAi Therapeutics (DNAI) Sees IPO Pricing of ~$17/Share, Above Previous Range
July 15, 2015 2:22 PM EDTProNAi Therapeutics, Inc. (Nasdaq: DNAI) filed a amended registration with the U.S. SEC for an IPO of its Common Stock. The company plans to sell 8.1 million shares and sees an offering price of about $17 per share. Previously, the company was planning to offer 6.7 million shares with an expected offering price of $14 to $16 per share. The company will trade on the Nasdaq Global Market under the ticker, "DNAI."
Underwriters are Jefferies, BofA Merrill Lynch, Wedbush PacGrow, and SunTrust Robinson Humphrey.
ProNAi Therapeutics... More
